ArticleMolecular biology reports2025
Prevalence of human papillomavirus (HPV) genotypes among outpatients referred to five laboratories in Shiraz, Iran.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHuman papillomavirus (HPV) is the most common sexually transmitted infection and a major cause of genital warts and anogenital cancers in both sexes. This study assessed HPV genotype distribution in a large outpatient population in southwestern Iran to inform preventive strategies. MATERIALS AND
methodsIn this cross-sectional study, 10,739 outpatient samples were collected from 2018 to 2023. Specimens included urine from men and vaginal swabs from women with normal cytology. HPV genotypes were assessed using DNA extraction, PCR and Direct Flow Chip method.
resultsHPV prevalence was 41.6% (94.8% in females, 5.2% in males). Women had a higher positivity rate (42.0%) than men (34.2%). The highest prevalence (44.3%) occurred in the 31-40 age group. High-risk types were present in 65.8% of positive cases. Women were more affected by high-risk genotypes, while low-risk types predominated in men. The most frequent high-risk genotypes were HPV-16, -53, -52, -66, and - 39; the most common low-risk types were HPV-6, -54, -42, -62, and - 44. Most individuals had a single infection. Mixed infections, more common in women, often involved both high- and low-risk types and showed greater diversity with age.
conclusionHPV prevalence, particularly of high-risk types, is notably high among women in southwestern Iran. The peak age of infection is higher than in developed countries. Differences in genotype distribution compared to American and other Iranian studies highlight the need for region-specific vaccination strategies targeting locally prevalent genotypes.
Indexed as
Identifiers
40932599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.